Rina Lokaj

Partial breast irradiation is associated with lower financial toxicities and fewer AEs in patients with early-stage breast cancer compared with whole breast irradiation.

Including minority populations in clinical trials can be most easily done through outreach and partnerships with other health centers, according to Adam B. Murphy, MD, MBA, MSCI.

The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Significant progression-free survival was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with maintenance selinexor.

The FDA finalizes the guidelines of its real-time oncology review to state that submissions must include clinical trial end points that can be “easily interpreted.”

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.

Researchers advise cancer providers to use online tools, visual aids, and interactive multimedia resources to educate patients before tumor testing.

A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.

Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.

The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%

Early CT screening leads to a 20-year lung cancer survival rate of 81%.

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Results from phase 1 of the RAMP 201 study shows efficacy in treating patients with recurrent low-grade serous ovarian cancer with avutometinib plus defactinib, regardless of previous treatment.

The partial clinical hold on a phase 1 study assessing NX-2127 in those with B-cell malignancies comes after the developer communicated intent to the FDA to move to a different manufacturing process.

Results from the phase 2 THIO-101 trial demonstrate disease control in all 19 patients with non–small cell lung cancer who received second-line THIO plus cemiplimab.

Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Study shows a high prevalence of thyroid cancer in transgender female patients.

Data from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial support the use of frontline dostarlimab plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.